Day One Biopharmaceuticals Inc.(DAWN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DAWN Day One Biopharmaceuticals Inc.

盘前交易 03-25 05:18:19 EDT

21.38

+0.02

+0.09%

最高21.38	最低21.34	成交量291.19万
今开21.36	昨收21.36	日振幅0.19%
总市值22.09亿	流通市值16.84亿	总股本1.03亿
成交额6,222万	换手率3.70%	流通股本7,877万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DAWN","market":"US","secType":"STK","nameCN":"Day One Biopharmaceuticals Inc.","latestPrice":21.38,"timestamp":1774382400000,"preClose":21.36,"halted":0,"volume":2911916,"delay":0,"changeRate":0.0009363295880149613,"floatShares":78766151,"shares":103297691,"eps":-1.039999,"marketStatus":"盘前交易","change":0.02,"latestTime":"03-25 05:18:19 EDT","open":21.36,"high":21.38,"low":21.34,"amount":62223693.44998799,"amplitude":0.001873,"askPrice":21.49,"askSize":250,"bidPrice":21.35,"bidSize":140,"shortable":3,"etf":0,"ttmEps":-1.039999,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774445400000},"marketStatusCode":1,"adr":0,"listingDate":1622088000000,"exchange":"NASDAQ","adjPreClose":21.38,"postHourTrading":{"tag":"盘后","latestPrice":21.4,"preClose":21.38,"latestTime":"17:46 EDT","volume":22809,"amount":487664.305,"timestamp":1774388763026,"change":0.02,"changeRate":0.000935,"amplitude":0.000935},"volumeRatio":0.6239996057018238,"impliedVol":0.0928,"impliedVolPercentile":0.048},"requestUrl":"/m/hq/s/DAWN","defaultTab":"news","newsList":[{"id":"1151567677","title":"Piper Sandler下调Day One Biopharmaceuticals评级至中性，目标价降至21.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151567677","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151567677?lang=zh_cn&edition=full","pubTime":"2026-03-06 23:29","pubTimestamp":1772810951,"startTime":"0","endTime":"0","summary":"投资银行Piper Sandler宣布，将生物制药公司Day One Biopharmaceuticals Inc.（股票代码：DAWN）的投资评级从\"增持\"下调至\"中性\"。同时，该机构将其目标股价从原先的25美元调降至21.5美元。这一调整反映了分析师对该公司短期前景的审慎评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DAWN","BK4139"],"gpt_icon":0},{"id":"1176430772","title":"Day One Biopharmaceuticals Inc.：若特定条件下交易终止，公司将向施维雅制药支付8770万美元终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1176430772","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176430772?lang=zh_cn&edition=full","pubTime":"2026-03-06 21:57","pubTimestamp":1772805432,"startTime":"0","endTime":"0","summary":"根据最新披露的条款，Day One Biopharmaceuticals Inc.与施维雅制药（Servier Pharmaceuticals）之间的合作协议约定，若交易因特定情形被终止，Day One Biopharmaceuticals Inc.需向后者支付高达8770万美元的终止费用。该条款旨在明确双方在合作意外中止时的财务责任，保障协议的稳定性与可执行性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DAWN","BK4539"],"gpt_icon":0},{"id":"1140722793","title":"施维雅与Day One Biopharmaceuticals宣布收购案，拓展施维雅罕见肿瘤产品组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1140722793","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140722793?lang=zh_cn&edition=full","pubTime":"2026-03-06 21:33","pubTimestamp":1772803997,"startTime":"0","endTime":"0","summary":"施维雅与Day One Biopharmaceuticals Inc.共同宣布一项收购协议，此举将显著增强施维雅在罕见肿瘤治疗领域的产品管线布局。通过本次战略收购，施维雅旨在加速其罕见肿瘤药物的研发与商业化进程，为全球患者提供更前沿的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DAWN","BK4139"],"gpt_icon":0},{"id":"1105655403","title":"赛维耶将以每股21.50美元收购Day One Biopharmaceuticals，股权总价值达25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105655403","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105655403?lang=zh_cn&edition=full","pubTime":"2026-03-06 21:33","pubTimestamp":1772803991,"startTime":"0","endTime":"0","summary":"生物制药企业Day One Biopharmaceuticals Inc.（纳斯达克代码：DAWN）宣布与法国制药巨头赛维耶（Servier）达成收购协议。根据条款，赛维耶将以每股21.50美元的价格全现金收购Day One全部流通股，对应股权总价值约为25亿美元。该交易已获双方董事会一致批准，预计将于2024年下半年完成，届时Day One将作为赛维耶全资子公司运营。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DAWN","BK4139","BK4539"],"gpt_icon":0},{"id":"1157732267","title":"Day One Biopharmaceuticals公布2025年第四季度及全年财务业绩，并重申2026年展望与营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1157732267","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157732267?lang=zh_cn&edition=full","pubTime":"2026-02-25 05:00","pubTimestamp":1771966813,"startTime":"0","endTime":"0","summary":"Day One Biopharmaceuticals Inc.（简称：Day One）已正式披露其2025财年第四季度以及全年度的财务报告。与此同时，公司管理层重申了对2026财年的业务发展前景及既定的营业收入指引，展现出对未来业绩表现的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DAWN","BK4139","BK4539"],"gpt_icon":0},{"id":"2613790860","title":"Day One Biopharmaceuticals, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613790860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613790860?lang=zh_cn&edition=full","pubTime":"2026-02-23 23:11","pubTimestamp":1771859468,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日23时11分，Day One Biopharmaceuticals, Inc.股票出现异动，股价急速跳水5.01%。Day One Biopharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。Day One Biopharmaceuticals, Inc.公司简介：Day One Biopharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发和商业化针对所有年龄段遗传性癌症患者的靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223231109a716487d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223231109a716487d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DAWN","BK4139","BK4539"],"gpt_icon":0},{"id":"1153563631","title":"财报前瞻 ｜Day One Biopharmaceuticals Inc.本季度营收预计增71.29%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1153563631","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153563631?lang=zh_cn&edition=full","pubTime":"2026-02-17 12:55","pubTimestamp":1771304140,"startTime":"0","endTime":"0","summary":"Day One Biopharmaceuticals Inc.将在2026年02月24日发布财报，市场关注营收高增与亏损收窄的节奏及利润率走向。发展前景最大的现有业务仍围绕核心产品的持续渗透和适应症扩展，随着核心产品放量，本季度总营收预计同比增71.29%，收入结构对整体增长贡献度高。结合一致预期，本季度营收预计同比增71.29%，息税前利润和调整后每股收益分别预计同比改善42.19%与55.80%，机构侧的核心观点围绕“规模放量带动亏损收窄、利润率边际改善”的主线展开。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Day One Biopharmaceuticals Inc.本季度营收预计增71.29%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DAWN"],"gpt_icon":0},{"id":"2605422056","title":"Day One Biopharmaceuticals, Inc.盘中异动 早盘股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605422056","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605422056?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:54","pubTimestamp":1769093672,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日22时54分，Day One Biopharmaceuticals, Inc.股票出现异动，股价大幅拉升5.05%。Day One Biopharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.63%。Day One Biopharmaceuticals, Inc.公司简介：Day One Biopharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发和商业化针对所有年龄段遗传性癌症患者的靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012222543297a2fa9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012222543297a2fa9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","DAWN"],"gpt_icon":0},{"id":"2605144638","title":"Day One Biopharmaceuticals, Inc.盘中异动 快速拉升6.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605144638","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605144638?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:50","pubTimestamp":1768920630,"startTime":"0","endTime":"0","summary":"北京时间2026年01月20日22时50分，Day One Biopharmaceuticals, Inc.股票出现波动，股价快速拉升6.20%。Day One Biopharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.90%。其相关个股中，Corvus Pharmaceuticals, Inc.、Rapt Therapeutics, Inc.、Aclaris Therapeutics, Inc.涨幅较大，Jaguar Health, Inc.、Rapt Therapeutics, Inc.、Dermata Therapeutics, Inc.较为活跃，换手率分别为90.87%、49.70%、47.35%，振幅较大的相关个股有Corvus Pharmaceuticals, Inc.、Cytomed Therapeutics Limited、Briacell Therapeutics Corp C/Wts ，振幅分别为46.96%、24.83%、23.60%。Day One Biopharmaceuticals, Inc.公司简介：Day One Biopharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发和商业化针对所有年龄段遗传性癌症患者的靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012022503197a29f95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012022503197a29f95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DAWN","BK4539","BK4139"],"gpt_icon":0},{"id":"1198566131","title":"Day One公布2025年Ojemda™净产品收入初步预测 并提供2026年净产品收入指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1198566131","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198566131?lang=zh_cn&edition=full","pubTime":"2026-01-12 06:00","pubTimestamp":1768168815,"startTime":"0","endTime":"0","summary":"生物制药公司Day One Biopharmaceuticals Inc.（以下简称Day One）今日公布了其核心产品Ojemda™在2025年的初步净产品收入预测，同时向市场提供了针对2026年的净产品收入指引。这一举措旨在向投资者和业界清晰展示公司对其重磅疗法未来商业表现的信心与预期。\nOjemda™作为公司研发管线中的关键资产，其收入预测是衡量公司未来增长潜力的重要指标。此次公布的指引不仅反映了市场对该产品的需求预期，也体现了公司在商业化执行方面的战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","DAWN"],"gpt_icon":0},{"id":"2593451473","title":"Day One Biopharmaceuticals, Inc.盘中异动 股价大涨5.09%报9.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593451473","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593451473?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:01","pubTimestamp":1766419267,"startTime":"0","endTime":"0","summary":"北京时间2025年12月23日00时01分，Day One Biopharmaceuticals, Inc.股票出现波动，股价大幅上涨5.09%。Day One Biopharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。Day One Biopharmaceuticals, Inc.公司简介：Day One Biopharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发和商业化针对所有年龄段遗传性癌症患者的靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122300010897a08eb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122300010897a08eb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DAWN","BK4539","BK4139"],"gpt_icon":0},{"id":"2592900091","title":"DePIN 项目 DAWN 完成 1300 万美元 B 轮融资，Polychain 领投","url":"https://stock-news.laohu8.com/highlight/detail?id=2592900091","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592900091?lang=zh_cn&edition=full","pubTime":"2025-12-18 23:42","pubTimestamp":1766072520,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方消息，去中心化自治无线网络项目 DAWN 宣布完成 1,300 万美元 B 轮融资，Polychain 领投。\n\n新资金将用于加速全球扩张、新部署和生态系统合作，DAWN 将继续致力于在全球范围内扩展去中心化宽带。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2230862","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","DAWN"],"gpt_icon":0},{"id":"2592947726","title":"Day One Biopharmaceuticals, Inc.盘中异动 下午盘股价大涨5.15%报8.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592947726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592947726?lang=zh_cn&edition=full","pubTime":"2025-12-18 02:09","pubTimestamp":1765994972,"startTime":"0","endTime":"0","summary":"北京时间2025年12月18日02时09分，Day One Biopharmaceuticals, Inc.股票出现波动，股价大幅拉升5.15%。Day One Biopharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。Day One Biopharmaceuticals, Inc.公司简介：Day One Biopharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发和商业化针对所有年龄段遗传性癌症患者的靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121802093297a06f8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121802093297a06f8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DAWN","BK4539","BK4139"],"gpt_icon":0},{"id":"2586041502","title":"Day One Biopharmaceuticals, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586041502","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586041502?lang=zh_cn&edition=full","pubTime":"2025-11-25 01:07","pubTimestamp":1764004041,"startTime":"0","endTime":"0","summary":"北京时间2025年11月25日01时07分，Day One Biopharmaceuticals, Inc.股票出现异动，股价快速拉升5.05%。Day One Biopharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Day One Biopharmaceuticals, Inc.公司简介：Day One Biopharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发和商业化针对所有年龄段遗传性癌症患者的靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125010722a70ebf03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125010722a70ebf03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DAWN","BK4539","BK4139"],"gpt_icon":0},{"id":"1161794390","title":"Day One公布Ojemda™ (Tovorafenib)第二阶段Firefly-1试验三年随访数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161794390","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161794390?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:01","pubTimestamp":1763989301,"startTime":"0","endTime":"0","summary":"Day One公布Ojemda™ (Tovorafenib)第二阶段Firefly-1试验三年随访数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DAWN","BK4539"],"gpt_icon":0},{"id":"1106872514","title":"Day One生物制药收购Mersana Therapeutics，以推进为各年龄段面临生命威胁疾病的人们带来新药的使命","url":"https://stock-news.laohu8.com/highlight/detail?id=1106872514","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106872514?lang=zh_cn&edition=full","pubTime":"2025-11-13 19:03","pubTimestamp":1763031797,"startTime":"0","endTime":"0","summary":"Day One生物制药收购Mersana Therapeutics，以推进为各年龄段面临生命威胁疾病的人们带来新药的使命","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DAWN","BK4539","BK4139"],"gpt_icon":0},{"id":"1173463873","title":"异动解读 | Day One生物制药盘中大涨5.04%，新药Ojemda™数据将在神经肿瘤学会年会报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1173463873","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173463873?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:51","pubTimestamp":1762789906,"startTime":"0","endTime":"0","summary":"Day One生物制药今日盘中大涨5.04%，引起投资者广泛关注。这一显著涨幅与公司最新发布的重要研究数据密切相关。据悉，Day One生物制药将在即将召开的2025年神经肿瘤学会年会上，通过口头报告形式公布其重磅新药Ojemda的最新数据。Ojemda是Day One的主打产品，其在神经肿瘤治疗领域的潜力备受市场期待。此次Ojemda数据被选为口头报告，表明其研究结果可能具有重要意义。投资者对这一潜在的突破性进展反应积极，推动Day One生物制药股价在盘中显著上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DAWN"],"gpt_icon":0},{"id":"1105795532","title":"异动解读 | Day One生物制药公司盘中大涨5.04%，新Ojemda™数据公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1105795532","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105795532?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:51","pubTimestamp":1762789903,"startTime":"0","endTime":"0","summary":"Day One生物制药公司在周一盘中大涨5.04%，引起了投资者的广泛关注。此次股价上涨主要受益于公司发布的最新消息。Day One生物制药公司宣布将在2025年神经肿瘤学会年会上公布其重要产品Ojemda 的最新数据，并将进行口头报告。投资者对这一消息反应积极，认为这可能会增强公司的市场竞争力，并有望带来可观的经济效益。这一积极信号推动了Day One生物制药公司股价的显著上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DAWN"],"gpt_icon":0},{"id":"1158912236","title":"Day One公布新Ojemda™ (Tovorafenib)数据，将在2025年神经肿瘤学会年会上进行口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1158912236","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158912236?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:01","pubTimestamp":1762776089,"startTime":"0","endTime":"0","summary":"Day One公布新Ojemda™ (Tovorafenib)数据，将在2025年神经肿瘤学会年会上进行口头报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","DAWN"],"gpt_icon":0},{"id":"1143245316","title":"Day One Biopharmaceuticals Inc. 上调2025年Ojemda全年净产品收入指引至1.45亿至1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143245316","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143245316?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:25","pubTimestamp":1762291555,"startTime":"0","endTime":"0","summary":"Day One Biopharmaceuticals Inc. 上调2025年Ojemda全年净产品收入指引至1.45亿至1.5亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DAWN","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dayonebio.com;ir.dayonebio.com","stockEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.8149},{"period":"3month","weight":1.2271},{"period":"6month","weight":2.2006},{"period":"1year","weight":1.5728},{"period":"ytd","weight":1.294}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Day One Biopharmaceuticals, Inc.于2018年11月在特拉华州注册成立为一家有限责任公司。作为一家商业化阶段的生物制药公司，该公司专注于开发针对儿童和成人疾病的首创或同类最佳药物。Day One采用搜索与开发战略来识别、收购和推进药物项目，其首个商业化产品是托沃拉非尼（tovorafenib）——一种口服、可穿透血脑屏障、高选择性的II型RAF激酶抑制剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.018311},{"month":2,"riseRate":0.2,"avgChangeRate":-0.086783},{"month":3,"riseRate":0.2,"avgChangeRate":0.066351},{"month":4,"riseRate":0.25,"avgChangeRate":-0.049371},{"month":5,"riseRate":0.25,"avgChangeRate":-0.150324},{"month":6,"riseRate":0.6,"avgChangeRate":0.358793},{"month":7,"riseRate":0.8,"avgChangeRate":0.035671},{"month":8,"riseRate":0.8,"avgChangeRate":0.129963},{"month":9,"riseRate":0.2,"avgChangeRate":-0.087961},{"month":10,"riseRate":0.8,"avgChangeRate":0.032302},{"month":11,"riseRate":0.4,"avgChangeRate":-0.008674},{"month":12,"riseRate":0.4,"avgChangeRate":0.016669}],"exchange":"NASDAQ","name":"Day One Biopharmaceuticals Inc.","nameEN":"Day One Biopharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Day One Biopharmaceuticals Inc.(DAWN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Day One Biopharmaceuticals Inc.(DAWN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Day One Biopharmaceuticals Inc.,DAWN,Day One Biopharmaceuticals Inc.股票,Day One Biopharmaceuticals Inc.股票老虎,Day One Biopharmaceuticals Inc.股票老虎国际,Day One Biopharmaceuticals Inc.行情,Day One Biopharmaceuticals Inc.股票行情,Day One Biopharmaceuticals Inc.股价,Day One Biopharmaceuticals Inc.股市,Day One Biopharmaceuticals Inc.股票价格,Day One Biopharmaceuticals Inc.股票交易,Day One Biopharmaceuticals Inc.股票购买,Day One Biopharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Day One Biopharmaceuticals Inc.(DAWN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Day One Biopharmaceuticals Inc.(DAWN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}